nach oben

Supportive Care in Cancer

Erschienen in:

01.03.2008 | Review Article

Biomarkers for cancer cachexia: is there also a genetic component to cachexia?

verfasst von: B. H. L. Tan, D. A. C. Deans, R. J. E. Skipworth, J. A. Ross, K. C. H. Fearon

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cancer cachexia is a severe debilitating disorder, which causes significant morbidity and mortality. In clinical practice, cachexia is often not treated until a late stage, when therapeutic options are limited.

Objective

It is therefore of great interest to analyse early biomarkers of this syndrome.

Conclusion

In this review article, we summarise recent biomarkers found in various body compartments. We also explore the likelihood of a genetic predisposition to cachexia and focus on the potential role of single nucleotide polymorphisms in genes coding for pro- and anti-inflammatory cytokines, and ‘atrogenes’ associated with wasting in skeletal muscle.

Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, Ringel MD, Skipworth RJ, Fearon KC, Hollingsworth MA, Muscarella P, Burghes AH, Rafael-Fortney JA, Guttridge DC (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8:421–432PubMedCrossRef

Argiles JM, Busquets S, Lopez-Soriano FJ (2003) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6:401–406PubMedCrossRef

Argiles JM, Moore-Carrasco R, Fuster G, Busquets S, Lopez-Soriano FJ (2003) Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 35:405–409PubMedCrossRef

Attaix D, Aurousseau E, Combaret L, Kee A, Larbaud D, Ralliere C, Souweine B, Taillandier D, Tilignac T (1998) Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. Reprod Nutr Dev 38:153–165PubMedCrossRef

Baracos VE (2006) Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 26:435–461PubMedCrossRef

Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA (2000) A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 83:1443–1447PubMedCrossRef

Barber MD, Powell JJ, Lynch SF, Gough NJ, Fearon KC, Ross JA (1999) Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin Exp Immunol 117:425–429PubMedCrossRef

Barton BE (2001) IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 23:41–58PubMedCrossRef

Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P (2004) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101:2500–2505PubMedCrossRef

10.

Broekhuizen R, Grimble RF, Howell WM, Shale DJ, Creutzberg EC, Wouters EF, Schols AM (2005) Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr 82:1059–1064PubMed

11.

Chlebowski RT, Heber D (1982) Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 42:2495–2498PubMed

12.

Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A, Grimble R, Fearon K (2007) Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 14:329–339PubMedCrossRef

13.

Deans C, Wigmore S, Paterson-Brown S, Black J, Ross J, Fearon KC (2005) Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 103:1810–1818PubMedCrossRef

14.

Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC (2006) Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95:1568–1575PubMedCrossRef

15.

DeJong CH, Busquets S, Moses AG, Schrauwen P, Ross JA, Argiles JM, Fearon KC (2005) Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 14:257–263PubMed

16.

Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75:2077–2082PubMedCrossRef

17.

Fearon KC, Preston T (1990) Body composition in cancer cachexia. Infusionstherapie 17(Suppl 3):63–66PubMed

18.

Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350PubMed

19.

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376PubMedCrossRef

20.

Gervaziev YV, Kaznacheev VA, Gervazieva VB (2006) Allelic polymorphisms in the interleukin-4 promoter regions and their association with bronchial asthma among the Russian population. Int Arch Allergy Immunol 141:257–264PubMedCrossRef

21.

Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58:2359–2365PubMed

22.

Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61PubMed

23.

Jagoe RT, Goldberg AL (2001) What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4:183–190PubMedCrossRef

24.

Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R (2007) Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25:845–851PubMedCrossRef

25.

Lecker SH, Solomon V, Mitch WE, Goldberg AL (1999) Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129:227S–237SPubMed

26.

Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4:250–255PubMedCrossRef

27.

Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, Kloters O, Hammer J, Buchler MW, Giese NA, Friess H (2005) Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 11:5802–5808PubMedCrossRef

28.

McPherron AC, Lee SJ (1997) Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94:12457–12461PubMedCrossRef

29.

Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–1216PubMedCrossRef

30.

Pisters PW, Cersosimo E, Rogatko A, Brennan MF (1992) Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery 111:301–310PubMed

31.

Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396–402PubMedCrossRef

32.

Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL (2007) Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 21:140–155PubMedCrossRef

33.

Sanders PM, Russell ST, Tisdale MJ (2005) Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 93:425–434PubMedCrossRef

34.

Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K (2003) Pneumococcal septic shock is associated with the interleukin-10–1082 gene promoter polymorphism. Am J Respir Crit Care Med 168:476–480PubMedCrossRef

35.

Schaur RJ, Fellier H, Gleispach H, Fink E, Kronberger L (1979) Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases. J Cancer Res Clin Oncol 93:281–285PubMedCrossRef

36.

Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682–2688PubMedCrossRef

37.

Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, Kojima M, Kangawa K, Kohno N (2003) Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9:774–778PubMed

38.

Skipworth RJ, Stewart GD, Ross JA, Guttridge DC, Fearon KC (2006) The molecular mechanisms of skeletal muscle wasting: implications for therapy. Surgeon 4:273–283PubMedCrossRef

39.

Stewart GD, Skipworth RJ, Fearon KC (2006) Cancer cachexia and fatigue. Clin Med 6:140–143PubMed

40.

Stoneking M (2001) Single nucleotide polymorphisms. From the evolutionary past. Nature 409:821–822PubMedCrossRef

41.

Tisdale MJ (1997) Biology of cachexia. J Natl Cancer Inst 89:1763–1773PubMedCrossRef

42.

Tisdale MJ (1997) Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 13:1–7PubMedCrossRef

43.

Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871PubMedCrossRef

44.

Tisdale MJ (2004) Cancer cachexia. Langenbecks Arch Surg 389:299–305PubMedCrossRef

45.

Tisdale MJ, Brennan RA, Fearon KC (1987) Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer 56:39–43PubMed

46.

Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M (1996) Characterization of a cancer cachectic factor. Nature 379:739–742PubMedCrossRef

47.

Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ (1998) Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 58:2353–2358PubMed

48.

Tracey KJ, Cerami A (1993) Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 9:317–343PubMedCrossRef

49.

Vuoristo MS (2007) The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma. Cancer Genet Cytogenet 176:54–57PubMedCrossRef

50.

Wieland BM, Stewart GD, Skipworth RJ, Sangster K, Fearon KC, Ross JA, Reiman TJ, Easaw J, Mourtzakis M, Kumar V, Pak BJ, Calder K, Filippatos G, Kremastinos DT, Palcic M, Baracos VE (2007) Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res 13:4984–4992PubMedCrossRef

51.

Wigmore SJ, Plester CE, Ross JA, Fearon KC (1997) Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 84:196–197PubMedCrossRef

52.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195–3199PubMedCrossRef

53.

Wolf I, Sadetzki S, Kanely H, Kundel Y, Pariente C, Epstein N, Oberman B, Catane R, Kaufman B, Shimon I (2006) Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106:966–973PubMedCrossRef

54.

Zhang D, Zheng H, Zhou Y, Tang X, Yu B, Li J (2007) Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer 7:45PubMedCrossRef

Titel: Biomarkers for cancer cachexia: is there also a genetic component to cachexia?
verfasst von: B. H. L. Tan
D. A. C. Deans
R. J. E. Skipworth
J. A. Ross
K. C. H. Fearon
Publikationsdatum: 01.03.2008
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 3/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0367-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Biomarkers for cancer cachexia: is there also a genetic component to cachexia?

Abstract

Introduction

Objective

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Introduction

Objective

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Multinational Association of Supportive Care in Cancer

Why patients with lung cancer do not want help with some needs

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study

Self-reported taste and smell changes during cancer chemotherapy

Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug

Barriers to referral to inpatient palliative care units in Japan: a qualitative survey with content analysis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie